GlobeNewswire

VistaJet Consolidates Its Global Leading Position and Grows 22% in 2017

Dela

The global aviation company is well placed to seize even larger market share in 2018

Key highlights for full year ending 31 December 2017:

  • Flight revenue up 22%
  • EBITDA up 28%
  • Particularly strong results in U.S. with flight hours up 39% 

NEW YORK, April 30, 2018 (GLOBE NEWSWIRE) --  VistaJet today, after concluding its annual audit, announced its results for Fiscal Year 2017. The Company, with operations based in Malta, delivered another incredibly strong performance consolidating its leading position globally, with flight revenue rising by 22% driven by the continued popularity of its unique and compelling subscription business model, and the broader trends in the market. It also saw its EBITDA rise by 28% on the back of its scalable infrastructure and technological advantage. The performance is in line with the upward trajectory VistaJet has experienced since it was founded, recording year-on-year organic compounded revenue growth of over 18% between 2008 and 2017.

Due to its global platform, VistaJet's diverse and broad customer base means that it is largely protected from political or economic uncertainty in any one market, and can benefit from positive economic results in each region. This was further demonstrated in 2017, as VistaJet saw growth in flight hours in all of its core markets, significant outperforming the overall market place. THE U.S. spearheaded this expansion, with +39% growth.

VistaJet continues to be the only business in the sector to offer a complete global portfolio of flight solutions, thanks to its Program, Direct and On Demand services*. This comprehensive product offering allows the company to offer tailorded solutions to each and every business jet user, anywhere, anytime, globally.

Thomas Flohr, VistaJet's Founder and Chairman, said:
"2017 has been another record year. Along with taking market share from full and fractional ownership in all the core markets, including the largest market in the world - the U.S., we reinforced our position as the brand of choice for the world's leading business leaders and entrepreneurs. In the last twelve months, we have flown more Chief Executives and Chairmen to more destinations than we ever have before.

Our strategy, both in terms of geography and services, is working. We continue to see sustainable growth across our business, and retain the ability to adapt our offer to meet demand in every region. It's particularly pleasing to see our entire portfolio of flight solutions reporting growth last year.

We head into 2018 in a fantastic position. Our unique fleet and technology platform ideally places us to lead the market and seize any new opportunities. We are committed to becoming the No.1 player in every market in which we operate, and we are on course to make fast progress towards that goal over the next twelve months."

Market conditions
The market as a whole has proved resilient over the past decade, recording consistent single-digit growth. This trend continued in 2017, as the global market grew by 5%, aircraft utilization has returned to levels not seen since the recession, and the number of hours is now at its highest level since 2008. 

In addition, there are a number of macrotrends supporting VistaJet's position in the market palce. A strong move away from asset ownership is now fully in force on every continent. Furthermore, the competitive global economic landscape demands business jets to be available anywhere at a moment's notice.

2018 Outlook
VistaJet is ideally placed for further long-term, sustainable growth. VistaJet one of the most technologically integrated companies in business aviation, providing customers with a seamless experience. The Company's proprietary infrastructure also allows VistaJet to scale the business much further and in the most cost effective way for its clients.

* VistaJet offers a complete portfolio of flight solutions - Program, Direct and On Demand:

  • Program: VistaJet's Program is the flight-hour subscription plan tailored around each corporation or individual's flying requirements, offering guaranteed access to the entire fleet, anytime and anywhere in the world.
  • Direct: The fastest way to start flying VistaJet. Customers can request a flight directly through the VistaJet app and the 24/7 sales team. Direct also grants access to preferential rates on empty legs and one-way flights, based on aircraft availability.
  • On Demand: For discerning travelers who fly occasionally, VistaJet offers ad hoc flights based on availability.

VistaJet Press Contact:
Jennifer Farquhar | M: +44 7834 335505 | jennifer.farquhar@vistajet.com

About VistaJet
VistaJet is the first and only global aviation company. On its fleet of over 70 silver and red business jets, VistaJet has flown corporations, governments and private clients to 187 countries, covering 96% of the world. Founded in 2004 by Thomas Flohr, the company pioneered an innovative business model where customers have access to an entire fleet whilst paying only for the hours they fly, free of the responsibilities and asset risks linked to aircraft ownership. VistaJet's signature Program membership offers customers a bespoke subscription of flight hours on its fleet of mid and long-range jets, to fly them anytime, anywhere. Customers can also request Direct one-off flights through the industry's first end-to-end booking app or a 24/7 global team.  

More VistaJet information and news at vistajet.com

A photo accompanying this announcement is available at http://resource.globenewswire.com/Resource/Download/a1294a76-d325-481b-af56-a2a69fb795cf




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: VistaJet Ltd via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum